Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: A cohort study

Sexually Transmitted Infections

Volumn 90, Issue 7, 2014, Pages 550-555

  Jensen, Kirsten E ^a   Thomsen, Louise T ^a   Schmiedel, Sven ^a   Frederiksen, Kirsten ^a   Norrild, Bodil ^b   Van Den Brule, Adriaan ^c   Iftner, Thomas ^d   Kjær, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; BACTERIAL DNA;

ADULT; ARTICLE; CHLAMYDIASIS; COHORT ANALYSIS; DENMARK; DISEASE COURSE; DNA DETERMINATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; PREVALENCE; STRUCTURED INTERVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CANCER GRADING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; EPIDEMIOLOGY; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COHORT STUDIES; DENMARK; DNA, BACTERIAL; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84911399937     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2013-051431     Document Type: Article

References (29)

1. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
2. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
3. Miller WC, Ko EM. Does chlamydial infection increase the risk of cervical dysplasia? Sex Transm Infect 2011;87:366-7.
4. Safaeian M, Quint K, Schiffman M, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 2010;102:1794-804.
5. Kim S, Arduino JM, Roberts CC, et al. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women. Sex Transm Dis 2011;38:587-97.
6. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116:110-15.
7. Dahlstrom LA, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2541-50.
8. Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111:431-9.
9. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007;120:650-5.
10. Castle PE, Escoffery C, Schachter J, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Transm Dis 2003;30:575-80.
11. Lehtinen M, Ault KA, Lyytikainen E, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011;87:372-6.
12. Greene W, Xiao Y, Huang Y, et al. Chlamydia-infected cells continue to undergo mitosis and resist induction of apoptosis. Infect Immun 2004;72:451-60.
13. Knowlton AE, Fowler LJ, Patel RK. Chlamydia induces Anchorage independence in 3T3 cells and detrimental cytological defects in an infected model. PLoS ONE 2013;8:e54022.
14. Rahkola P, Vaisanen-Tommiska M, Hiltunen-Back E, et al. Cervical nitric oxide release in Chlamydia trachomatis and high-risk human papillomavirus infection. Acta Obstet Gynecol Scand 2011;90:961-5.
15. Williams VM, Filippova M, Soto U, et al. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol 2011;6:45-57.
16. Felley-Bosco E. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev 1998;17:25-37.
17. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. Natl Cancer Inst Monogr 2003;31:80-8.
18. Klug SJ, Molijn A, Schopp B, et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008;80:1264-74.
19. Morre SA, Sillekens P, Jacobs MV, et al. RNA amplification by nucleic acid sequence-based ampli fication with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples. J Clin Microbiol 1996;34:3108-14.
20. Munk C, Morre SA, Kjaer SK, et al. PCR-detected Chlamydia trachomatis infections from the uterine cervix of young women from the general population: prevalence and risk determinants. Sex Transm Dis 1999;26:325-8.
21. Jacobs MV, van den Brule AJ, Snijders PJ, et al. A non-radioactive PCR enzyme-immunoassay enables a rapid identi fication of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. J Med Virol 1996;49:223-9.
22. Jensen KE, Schmiedel S, Frederiksen K, et al. Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2012;21:1959-65.
23. Jensen KE, Schmiedel S, Norrild B, et al. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer 2013;108:234-9.
24. Dugue P-A, Rebolj M, Garred P, et al. Immunesuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013;13:29-42.
25. Nielsen A, Iftner T, Munk C, et al. Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis 2009;36:309-15.
26. Hwang LY, Scott ME, Ma Y, et al. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol 2011;88:66-71.
27. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-17.
28. Khan MJ, Partridge EE, Wang SS, et al. Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer 2005;104:61-70.
29. Carey AJ, Beagley KW. Chlamydia trachomatis, a hidden epidemic: effects on female reproduction and options for treatment. Am J Reprod Immunol 2010;63:576-86.